Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
IAS 2007: Sydney, Australia; July 22-25

Key Links:

By Topic:

Search:

  
  • Email Email
  • Glossary Glossary

Interviews With Researchers at IAS 2007

Daily Summaries

Joel Gallant, M.D.
  • IAS 2007: Day Three & Conference Roundup
    Joel Gallant, M.D., M.P.H., wraps up our daily recap series with a wide-ranging discussion of important studies on first-line therapy, therapy options for treatment-experienced patients, antiretrovirals in development, abacavir hypersensitivity testing and the metabolic impact of antiretroviral switching.
  • Daniel Berger, M.D.
  • IAS 2007: Day Two
    Daniel Berger, M.D., discusses thought-provoking research on recently approved antiretrovirals and drugs in development, including darunavir, MK-0518 (raltegravir), TMC278 (rilpivirine) and CCR5 inhibitors.
  • Daniel Berger, M.D.
  • IAS 2007: Day One
    Daniel Berger, M.D., recaps early research highlights from the conference, from HIV/hepatitis C coinfection to orally bioavailable fusion inhibitors in development.
  • IAS 2007 Highlights

    Daniel Berger, M.D.
  • Daniel Berger, M.D., NorthStar Healthcare and University of Illinois, Chicago, Ill.
    Most HIV conference coverage is geared toward medical professionals. Listen or read this interview with Daniel Berger, M.D., to get a more down-to-earth summary of some of the biggest research to come out of IAS 2007.
  • Calvin J. Cohen, M.D., M.S.
  • Calvin J. Cohen, M.D., M.S., Community Research Initiative of New England and Harvard Medical School, Boston, Mass.
    Dr. Cohen discusses the role of new agents in suppressing HIV.
  • Eric Daar, M.D.
  • Eric Daar, M.D., Chief of HIV Medicine, Harbor-UCLA Medical Center, Los Angeles, Calif.
    Dr. Daar discusses what he considers to be the two big studies of IAS 2007, the ongoing debate about when-to-start treatment, and his own take on circumcision as prevention in the developed world.
  • Steven G. Deeks, M.D.
  • Steven G. Deeks, M.D., Associate Professor in the Department of Medicine at UCSF and a faculty member in the Positive Health Program (HIV/AIDS division) at San Francisco General Hospital
    Dr. Deeks discussed SMART substudy results and weighed in on the when-to-start HIV treatment debate.
  • Anthony Fauci, M.D., Director of the U.S. National Institute of Allergy and Infectious Diseases
    Dr. Fauci and Dr. Daniel Berger discuss treatment and prevention strategies in the developing world and touch on gene therapy and the possibility of HIV eradication.
  • Trevor Hawkins, M.D., Medical Director of Southwest CARE Center, Santa Fe, and Associate Clinical Professor at the University of New Mexico
    Dr. Hawkins discusses the TITAN study, reviewing the relative side effects profiles of darunavir (TMC114, Prezista) + ritonavir (Norvir) and lopinavir/ritonavir (Kaletra), and the study's implications on clinical practice.
  • Mark Holodniy, M.D.
  • Mark Holodniy, M.D., Professor of Medicine, Stanford University, Stanford, Calif., and Director of the HIV Clinical Program and Public Health Research Center at the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.
    Dr. Holodniy summarized what he thought were IAS 2007 highlights.
  • Anthony Mills, M.D.
  • Anthony Mills, M.D., private practice, Los Angeles, Calif.
    Dr. Mills discusses how earlier HIV treatment may also prevent new HIV infections.
  • Pietro Vernazza, M.D.
  • Pietro Vernazza, M.D., Infectious Diseases, Department of Medicine, Cantonal Hospital, St. Gallen, Switzerland
    Dr. Vernazza offers his take on the when-to-start HIV treatment debate, circumcision and cardiovascular complications.
  • IAS 2007 Study Summaries

  • Sandrine Buisson, Imperial College London, United Kingdom
    Dr. Buisson discusses her research, which shows that monocyte-derived dendritic cells from HIV-infected people have impaired functions that are not resolved by antiretroviral therapy.
  • Edwin DeJesus, M.D., F.A.C.P.
  • Edwin DeJesus, M.D., F.A.C.P., Medical Director, Orlando Immunology Center
    Dr. DeJesus discusses data supporting the possibility that at least some cross-resistance occurs between the integrase inhibitors in development: elvitegravir (GS 9137) and raltegravir (MK-0518).
  • Sonia Fernandez, University of Western Australia, School of Surgery and Pathology, Perth, Australia
    Sonia Fernandez describes her poster, which shows that impaired CMV-specific CD4+ cell responses in HIV patients responding to antiretroviral therapy may reflect reductions in the proportions of plasmacytoid dendritic cells rather than changes in regulatory cytokines.
  • Linda Gelgor, Ph.D., National Centre in HIV Epidemiology and Clinical Research, Australia
    Dr. Gelgor discusses determinants associated with asymptomatic HIV in the Australian long-term non-progressor cohort.
  • Mark Holodniy, M.D.
  • Mark Holodniy, M.D., Professor of Medicine at Stanford University, Stanford, Calif., and Director of the HIV Clinical Program and Public Health Research Center at the Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif.
    Dr. Holodniy discussed his poster looking at baseline antiretroviral resistance and correlation with clinical events in the OPTIMA trial.
  • Benoit Marin
  • Benoît Marin, French National Institute for Health and Medical Research (INSERM U593), Cascade Group, Bordeaux, France
    Dr. Marin discusses the association between CD4+ count and viral load and death due to non-AIDS causes.
  • Anthony Mills, M.D.
  • Anthony Mills, M.D., private practice, Los Angeles, Calif.
    Dr. Mills discusses the results of the DUET-1 trial, a double-blind, placebo-controlled, phase 3 trial designed to assess the efficacy and safety of TMC125 (etravirine) in treatment-experienced patients with NNRTI and PI resistance.
  • Nancy Padian, Ph.D., Director of International Programs at University of California, San Francisco AIDS Research Institute
    Dr. Padian summarizes her plenary presentation on prevention technologies such as microbicides, dental dams and the female condom. Dr. Padian then answers questions on her presentation.
  • Marcello Pinti, Ph.D., University of Modena and Reggio Emilia, Department of Biomedical Sciences, Modena, Italy
    Dr. Pinti discusses his poster on the role of the PRSS15/LON gene during lipodystrophy.
  • Suraiya Rasheed, Ph.D., Keck School of Medicine, University of Southern California, Laboratory of Viral Oncology, AIDS and Proteomics Research Pathology Department, Los Angeles, Calif.
    Dr. Rasheed describes her research, which has shown that HIV infection of CD4+ cells enhances production of proteins associated with cardiovascular and other metabolic disorders.
  • Daniel J. Skiest, M.D.
  • Daniel J. Skiest, M.D., Director of HIV Services Baystate Medical Center
    Dr. Skiest discusses ACTG 5170 quality of life results showing that patients who had a high CD4+ cell count before a treatment interruption saw their medication-related symptoms improve during the treatment interruption.
  • Annette Sohn, M.D., Assistant Professor in the Division of Pediatric Infectious Diseases of the University of California, San Francisco, Vietnam Country Representative for the UCSF Institute for Global Health
    Dr. Sohn summarizes her plenary presentation on pediatric treatment issues and answers questions about global pediatric HIV.
  • Jonathan Uy, M.D.
  • Jonathan Uy, M.D., Assistant Professor of Medicine, Department of Medicine, University of Illinois at Chicago
    Dr. Uy discusses how the initiation of HAART at a CD4+ cell count of 350 cells/mm3 is associated with a lower prevalence of antiretroviral resistance mutations at virologic failure.
  • Pietro Vernazza, M.D.
  • Pietro Vernazza, M.D., Infectious Diseases, Department of Medicine, Cantonal Hospital, St. Gallen, Switzerland
    Dr. Vernazza discusses his poster on pre-exposure prophylaxis and timed unprotected intercourse for HIV-discordant heterosexual couples wanting to conceive a child.
  • Shauna Williams, M.D., UMDNJ-New Jersey Medical School, Obstetrics, Gynecology and Women's Health, Newark, N.J.
    Dr. Williams discusses her research on pregnancy and neonatal outcomes of perinatally-HIV-infected adolescents and young adults, including her finding that participants had high rates of other sexually transmitted diseases, in spite of being perinatally infected.
  • Pre-Conference Interviews

  • IAS 2007 Preview
    Daniel Berger, M.D., offers a look at the research this conference holds in store.
  • Copyright © 2007 Body Health Resources Corporation. All rights reserved. Podcast disclaimer


      
    • Email Email
    • Glossary Glossary

    Advertisement